Kinase gene fusions in defined subsets of melanoma
暂无分享,去创建一个
Jennifer D. Hintzsche | Carol Amato | Eric Seelenfreund | Joshua Wisell | Allison Applegate | John Tentler | M. Varella‐Garcia | A. Tan | J. Tentler | S. Robinson | J. Sheren | Aik-Choon Tan | Marileila Varella-Garcia | C. Amato | W. Robinson | S. Bagby | Steven Robinson | J. Wisell | Jacqueline Turner | Kasey Couts | Jamie Sheren | Siriwimon Saichaemchan | Witthawat Ariyawutyakorn | Izabela Avolio | Ethan Cabral | Magdelena Glogowska | Jennifer Hintzsche | Rita Gonzalez | Keith Wells | Stacey Bagby | William Robinson | Jacqueline A Turner | Jacqueline A. Turner | K. Wells | Allison Applegate | K. Couts | S. Saichaemchan | W. Ariyawutyakorn | Eric Seelenfreund | Izabela Avolio | Ethan Cabral | Magdelena Glogowska | R. Gonzalez | M. Varella-Garcia | A. Tan | S. Saichaemchan
[1] I. Yeh,et al. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.
[2] B. Bastian,et al. From melanocytes to melanomas , 2016, Nature Reviews Cancer.
[3] J. Reis-Filho,et al. High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform , 2011, Laboratory Investigation.
[4] I. McLean,et al. Uveal melanoma , 1997, Cancer.
[5] John A Thompson,et al. Treatment of metastatic melanoma: an overview. , 2009, Oncology.
[6] S. Ariyan,et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.
[7] F. Cappuzzo,et al. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[8] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[9] D. Morton,et al. Surgery for distant melanoma metastasis. , 2012, Cancer journal.
[10] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[11] K. Tsuta,et al. BRAF V600 mutations and pathological features in Japanese melanoma patients , 2014, Melanoma research.
[12] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[13] Kazuhiro Takahashi,et al. BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.
[14] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[15] Dirk Schadendorf,et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.
[16] Iwei Yeh,et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.
[17] P. Jänne,et al. Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease , 2014, PloS one.
[18] Subhajyoti De,et al. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples , 2016, J. Am. Medical Informatics Assoc..
[19] Junfeng Xia,et al. Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance , 2022 .
[20] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[21] A. Gown,et al. Quality control in immunohistochemistry. Report of a workshop sponsored by the Biological Stain Commission. , 1989, American journal of clinical pathology.
[22] L. Karnell,et al. The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.
[23] Frank McCormick,et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.
[24] P. Stephens,et al. BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition , 2013, Clinical Cancer Research.
[25] Jason Wang,et al. The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[26] V. Schabert,et al. Comparative healthcare costs in patients with metastatic melanoma in the USA , 2015, Melanoma research.
[27] A R Forrest,et al. Quality control. , 1978, British medical journal.
[28] Caroline Robert,et al. Safety and efficacy of vemurafenib in BRAF V 600 E and BRAF V 600 K mutation-positive melanoma ( BRIM-3 ) : extended follow-up of a phase 3 , randomised , open-label study , 2015 .
[29] F. Schmidt. Meta-Analysis , 2008 .
[30] Arun D. Singh,et al. Uveal melanoma: trends in incidence, treatment, and survival. , 2011, Ophthalmology.
[31] R. Scolyer,et al. Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma , 2009, Oncogene.
[32] Iwei Yeh,et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.
[33] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[34] D. Whiteman,et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Lauren E Haydu,et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.
[36] L. Thomas,et al. Acral lentiginous melanoma: histopathological prognostic features of 121 cases , 2007, The British journal of dermatology.
[37] J. Q. Rosso,et al. Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005 , 2010 .
[38] N. Lu,et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] Wei Li,et al. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas , 2013, Pigment cell & melanoma research.
[40] L. Garraway,et al. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.
[41] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[42] I. Yeh,et al. Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors , 2015, Nature Communications.
[43] M. Dimon,et al. An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples , 2015, PloS one.
[44] J. Bulliard,et al. Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] F. Hirsch,et al. ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer , 2014, Clinical lung cancer.
[46] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[47] Y. Chan,et al. Expression of Trk receptors in otolith-related neurons in the vestibular nucleus of rats , 2005, Brain Research.
[48] Kai Wang,et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy , 2015, International journal of cancer.
[49] L. Hirst,et al. Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia , 2000, Ophthalmic epidemiology.
[50] Targeted therapy in leukemia , 2008, Modern Pathology.
[51] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[52] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.